Bryan Health Signs Medline as Primary Medical Supplies Distributor

Nebraska-based healthcare system and Medline partner to enhance supply chain strategy and outcomes

Medline today announced it has entered into a multi-year prime vendor partnership, valued at $140M, with Nebraska-based Bryan Health. After being with a different distributor for over 30 years, the two organizations will collaborate to identify new strategies for enhancing patient outcomes and streamlining supply chain operations for the healthcare system. As the system’s primary supplier, Medline will exclusively provide an extensive portfolio of essential medical supplies and solutions to Bryan’s acute care medical centers in Lincoln, Grand Island, Crete and Central City, in addition to Kearney Regional Medical Center, which is already served by Medline.

“Medline’s proactive approach facilitated a smooth implementation and the customer support has been incredibly responsive,” said Heather Seeba, director of supply chain for Bryan Health. “We look forward to partnering with the Medline experts to optimize our operational processes and improve our supply consistency.”

As part of the agreement, dedicated Medline resources will work with Bryan Health to help address specific caregiver needs and operational efficiencies to support the system’s efforts in providing the highest quality of care for those they serve throughout the region. Bryan Health will also have the ability to easily monitor key metrics such as item utilization, contract compliance, price accuracy and spending by product categories through advanced analytics platforms from Medline.

“Medline is committed to providing Bryan Health with continuously reliable, superior service,” said Megan Schwellenbach, vice president of corporate accounts at Medline. “We are excited to enter into this prime vendor partnership and together develop solutions to help provide consistency and stability to its supply chain.”

SourceMedline

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version